15 results
8-K
EX-3.1
THRX
Theseus Pharmaceuticals Inc
14 Feb 24
Completion of Acquisition or Disposition of Assets
10:44am
be a conflict of interest or position on any significant issue between the Corporation and Indemnitee in the conduct of the defense of such action, suit
8-K
EX-2.1
THRX
Theseus Pharmaceuticals Inc
22 Dec 23
Entry into a Material Definitive Agreement
6:36am
has been authorized by the Corporation, (ii) counsel to Indemnitee shall have reasonably concluded that there may be a conflict of interest or position
PRE 14A
THRX
Theseus Pharmaceuticals Inc
14 Apr 23
Preliminary proxy
9:00am
for 2023. After review and consultation with Radford, the Compensation Committee determined that Radford is independent and that there is no conflict … of interest resulting from retaining Radford in 2022 or in 2023. In reaching these conclusions, our Compensation Committee considered the factors set
S-1/A
EX-10.1
THRX
Theseus Pharmaceuticals Inc
30 Sep 21
IPO registration (amended)
6:33am
a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. The Company
S-1
EX-4.2
1y9epsar0lvcpmq
15 Sep 21
IPO registration
4:04pm
S-1
EX-10.13
z568rhv6gayziujuj5
15 Sep 21
IPO registration
4:04pm
S-1
EX-10.9
57z8f1
15 Sep 21
IPO registration
4:04pm
S-1
EX-10.14
1x6708limtgx1yq
15 Sep 21
IPO registration
4:04pm
S-1
EX-10.11
gzx4n8
15 Sep 21
IPO registration
4:04pm
S-1
EX-10.12
fkn i5semzwqb5ag
15 Sep 21
IPO registration
4:04pm
S-1
EX-10.8
at2ar6bm8p
15 Sep 21
IPO registration
4:04pm
S-1
EX-10.10
m735nwq8qo
15 Sep 21
IPO registration
4:04pm
DRS/A
EX-10.14
fsc05tfgetvfd
23 Aug 21
Draft registration statement (amended)
12:00am
DRS/A
EX-4.2
po42mp5ka8 o8zx1
23 Aug 21
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next